MYRIAD GENETICS INC (MYGN)
US62855J1043 - Common Stock
Myriad Genetics to Host Investor Event on October 9, 2024
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
SALT LAKE CITY, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Thermo Fisher Scientific Stock Sees RS Rating Jump To 81
Thermo Fisher Scientific stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, rising from 77 to 81.
MYGN Stock Earnings: Myriad Genetics Beats EPS, Beats Revenue for Q2 2024
MYGN stock results show that Myriad Genetics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
SALT LAKE CITY, July 31, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Avantor Stock Earns 84 RS Rating
Avantor stock had its Relative Strength (RS) Rating upgraded from 78 to 84 Tuesday amid positive Q2 earnings results.
Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer
What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
New Nationwide Survey Findings Show That More Than Half of Women Do Not Know That Breast Density Can Reveal Increased Risk of Breast Cancer...
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision...
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
SALT LAKE CITY, July 09, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
The 3 Best Gene Editing Stocks to Buy in July 2024
Gene editing is revolutionizing medicine, creating substantial opportunities for some of the best gene editing stocks.
Myriad Genetics Earns 2024 Great Place To Work® Certification™
Myriad Genetics Earns 2024 Great Place To Work® Certification™
SALT LAKE CITY, July 02, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health
Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election
New Findings from Myriad Genetics Reveal One-Third of Americans Say Election Season Affects Their Mental Health...
Interesting MYGN Put And Call Options For February 2025
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer
Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries
New sponsored testing program leverages Myriad’s MyChoice Tests for patients with high-grade serous ovarian cancer...
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen
SALT LAKE CITY, June 04, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool
SALT LAKE CITY, June 03, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today...
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators
Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting
Molecular Residual Disease (MRD) study and multiple RiskScore studies among seven new datasets to be shared by Myriad and Collaborators ...
New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
Myriad’s Prolaris Test is the only biomarker test to quantify the benefits of adding androgen deprivation therapy to radiation therapy1 SALT LAKE CITY,...
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Genomics is the future of medicine, creating big opportunity for some of the top genomics stock picks to buy today.